Navigation Links
Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
Date:5/2/2012

SAN DIEGO, May 2, 2012 /PRNewswire/ -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Zohydro™ (hydrocodone bitartrate extended-release capsules), Zogenix's lead investigational product candidate for the treatment of chronic pain.    

Zohydro is a novel, oral, single-entity (without acetaminophen) extended-release formulation of various strengths of hydrocodone intended for administration every 12 hours  for around the clock management of moderate to severe chronic pain. If approved, Zohydro could be the first hydrocodone product to offer the benefit of less frequent dosing and the ability to treat patients with chronic pain without the risk of acetaminophen-related liver injury.  Currently, hydrocodone is only available in immediate-release, combination products, most commonly with the analgesic acetaminophen, and requires dosing every 4 to 6 hours. Zohydro, classified as a Drug Enforcement Agency (DEA) Schedule II drug product, would carry more strict prescription and dispensing rules as compared to the currently available hydrocodone combination products. In addition, Zogenix has included in the NDA a comprehensive Risk Evaluation and Mitigation Strategy (REMS) that is consistent with current FDA and industry-wide guidelines for extended-release opioid products. The REMS is intended to control inappropriate prescribing, misuse and abuse of extended-release opioids while maintaining patient access to essential pain medications.

"The NDA submission for Zohydro is a significant milestone, bringing us another step closer to making this important acetaminophen-free hydrocodone treatment option availa
'/>"/>

SOURCE Zogenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Zogenix Secures $35 Million Debt Facility and Raises $15 Million Investment Capital
2. Zogenix Initiates Pivotal Phase 3 Clinical Trial for Novel Formulation of Oral Controlled-Release Hydrocodone
3. Cardinal Health Specialty Solutions Submits 1,000th Electronic Common Technical Document (eCTD) to FDA
4. Marshall Edwards Submits Investigational New Drug Application for Oncology Drug Candidate ME-344
5. Octapharma USA Submits BLA for octaplasLG®, a Therapy Targeting Adverse Transfusion Events
6. Intellect Neurosciences Submits Statement Setting Grounds for Appeal in European Patent Proceedings
7. Arena Submits Response to FDA Complete Response Letter for Lorcaserin
8. Janssen Research & Development Submits Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
9. Radient Pharmaceuticals Submits an Abstract to the American Society of Colon and Rectal Surgeons
10. Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin
11. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 Doctors from the Sheikh Zayed ... National Health System are the first in ... osteoma, a benign but painful bone tumor that commonly ... magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) method. Two patients, ... Shah , have been treated successfully in a research ...
(Date:5/27/2015)... 2015 The report " Tube Packaging Market ... Oral Care, Food & beverages, Pharmaceuticals, Consumer Goods), by Material ... - Trends & Forecasts to 2020", published by MarketsandMarkets, The ... a CAGR of 6.65% from 2015, to reach $8,638.9 Million ... Tables and   61 F igures spread thro ...
(Date:5/27/2015)... , May 27, 2015  Vital Access Corp. announced ... credit facility with Deerfield Management, a healthcare investment firm. ... Vital Access, continued global expansion of its innovative VWING™ ... the Company,s proprietary vascular access platform. "Vital ... financial partner. Deerfield is a healthcare investor with great ...
Breaking Medicine Technology:Children's National first in US to destroy bone tumors with incisionless surgery 2Children's National first in US to destroy bone tumors with incisionless surgery 3Children's National first in US to destroy bone tumors with incisionless surgery 4Tube Packaging Market Worth $8.63 Billion by 2020 2Tube Packaging Market Worth $8.63 Billion by 2020 3Tube Packaging Market Worth $8.63 Billion by 2020 4Vital Access Receives $10 Million Financing Commitment from Deerfield 2Vital Access Receives $10 Million Financing Commitment from Deerfield 3
(Date:5/27/2015)... Dr. Omar Ibrahimi, Dermatologist and Director ... has been selected as part of a controlled launch ... the only physician in Connecticut) to offer the new ... removal of submental fat (double chin). The procedure is ... surgery and minimal risks. Dr. Ibrahimi is an invited ...
(Date:5/27/2015)... 27, 2015 In support of a ... issue of the Journal of American Geriatrics Society about ... obesity, Bedford Commons OB-GYN P.A . is reiterating ... sweetener-flavored beverages. , To examine the relationship between ... San Antonio Longitudinal Study of Aging (SALSA) tracked the ...
(Date:5/27/2015)... SAN DIEGO, May 27, 2015 – Memorial ... healthcare provider along the Gulf Coast to pioneer ... In partnership with MD Revolution, a digital care ... program that enables healthcare providers to easily meet ... new, user-friendly program is designed to improve patient ...
(Date:5/27/2015)... On June 5, Plan B [the agency ... LifeSource to host Donate Your Break, a public blood ... LifeSource donor coach outside of 116 W. Illinois (at ... for whole blood units is highest for LifeSource, the ... LifeSource requires approximately 1,000 donations per day to maintain ...
(Date:5/27/2015)... Meadows, IL (PRWEB) May 27, 2015 ... release of its SonarMD Platform, a first-of-its ... monitoring and managing patients with chronic gastrointestinal ... Kosinski, MD, MBA, the application allows physicians ... visits through the ongoing use of electronic ...
Breaking Medicine News(10 mins):Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:Recent Study About the Link Between Diet Sodas and Abdominal Fat Reinforces Bedford Commons OB-GYN's Recommendation to Drink Plenty of Water 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:SonarMD™, LLC, Launches Game-Changing, IBD Population Health Management Platform 2
... LAKE CITYFindings of a clinical trial reported at SNM,s ... agent could improve diagnosis of recurrent prostate cancer and ... "Despite definitive treatment, about 30 percent ... of the division of nuclear medicine and molecular imaging ...
... Public Health (HSPH) have found that children and adolescents ... smoke-free public places have significantly lower levels of a ... in counties with no smoke-free laws. The children ... laws had 39% lower prevalence of cotinine in their ...
... results from a major clinical trial show that ... women with advanced ovarian cancer and then continuing ... extends progression-free survival. Women receiving the new treatment ... 14.1 months, compared to 10.3 months for women ...
... June 5 The combination of two different chemotherapies ... cancers is not effective against advanced melanoma, according to ... 46th annual meeting of the American Society of Clinical ... we learn something important about the treatment of melanoma," ...
... and Tasigna than Gleevec , SATURDAY, June 5 (HealthDay ... (Tasigna), appear better than imatinib (Gleevec) in treating patients ... considered as first-line treatments, two new studies show. , ... be presented Saturday at the American Society of Clinical ...
... -- Two drugs approved for treatment of drug-resistant chronic ... a first therapy than the existing front-line medication, according ... England Journal of Medicine . Separate international ... year of treatment between the standard-of-care drug imatinib, also ...
Cached Medicine News:Health News:Molecular imaging detects recurrent prostate cancer 2Health News:Smoke-free air laws effective at protecting children from secondhand smoke 2Health News:New treatment regimen shown effective against advanced ovarian cancer 2Health News:Combination treatment regimen not effective against advanced melanoma 2Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 2Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 3Health News:Newer Drugs Beat Gleevec in Head-to-Head Trials 4Health News:Second-line CML drugs evoke faster, better front-line remissions 2Health News:Second-line CML drugs evoke faster, better front-line remissions 3
... The OcuLight family of infrared laser ... SLx models. These diode lasers serve as ... devices and applications, require no regular maintenance ... with their compact design. The OcuLight SLx ...
... mid range space saver specular microscope. It has ... the corneal endothelium automatically. It also has the ... central area. The image of the cells is ... with the system., This model is exactly the ...
... Danker Laboratories manufacturers ... RGP orthokeratology lenses (also ... or "Corneal Reshaping" Lenses) ... specifications and demanding standards ...
... The JSZ Orthokeratology (oprifocon A) ... permeable contact lenses used for ... corrects nearsightedness (myopia). The patient ... removes them in the morning. ...
Medicine Products: